SCHEMBL4713699

SCHEMBL4713699

COCc1ccc(C(=O)COCc2cc(S(=O)(=O)N3CCCCC3)c(Cl)cc2Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MAPT P10636 1/20 0.47
RECQL P46063 1/20 0.47
TDP1 Q9NUW8 6/20 0.47
APEX1 P27695 1/20 0.47
RAB9A P51151 2/20 0.46
POLB P06746 3/20 0.46
HTT P42858 1/20 0.46
AGTR1 P30556 1/20 0.44
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
NPBWR1 P48145 1/20 0.43
MCHR1 Q99705 1/20 0.43
HPGD P15428 1/20 0.43
LMNA P02545 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4713451 0.90 ALDH1A1 (0.43) ALDH1A1L3MBTL1MAPTRECQLTDP1
SCHEMBL5746636 0.89 MAPT (0.40) ALDH1A1L3MBTL1MAPTRECQLTDP1
SCHEMBL4715337 0.87 ALDH1A1 (0.50) ALDH1A1L3MBTL1TDP1APEX1POLB
SCHEMBL4713899 0.83 POLB (0.47) ALDH1A1L3MBTL1MAPTTDP1APEX1
SCHEMBL4713378 0.82 TDP1 (0.47) ALDH1A1TDP1APEX1POLBHTT
SCHEMBL4713747 0.82 ALDH1A1 (0.46) ALDH1A1L3MBTL1TDP1APEX1RAB9A
SCHEMBL4715341 0.81 ALDH1A1 (0.41) ALDH1A1L3MBTL1MAPTRECQLTDP1
SCHEMBL4761408 0.81 ALDH1A1 (0.41) ALDH1A1L3MBTL1MAPTRECQLTDP1
SCHEMBL4716090 0.78 ALDH1A1 (0.46) ALDH1A1L3MBTL1TDP1APEX1RAB9A
SCHEMBL5737777 0.76 ALDH1A1 (0.40) ALDH1A1L3MBTL1MAPTTDP1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615904-B1 SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS ASTRAZENECA AB (SE) 2008-02-27 EP claimed
US-20070021606-A1 Therapeutic compounds ASTRAZENECA AB (SE) 2007-01-25 US claimed
EP-1615904-B1 SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS ASTRAZENECA AB (SE) 2008-02-27 EP disclosed
EP-1615904-B1 SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS ASTRAZENECA AB (SE) 2008-02-27 EP disclosed
US-20070021606-A1 Therapeutic compounds ASTRAZENECA AB (SE) 2007-01-25 US disclosed
US-20070021606-A1 Therapeutic compounds ASTRAZENECA AB (SE) 2007-01-25 US disclosed
US-20070021606-A1 Therapeutic compounds ASTRAZENECA AB (SE) 2007-01-25 US disclosed
WO-2004092135-A2 SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS ASTRAZENECA (SE) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021606-A1 Therapeutic compounds GRIN1, GRIN3A, GRM2 ALDH1A1 1721/4885L3MBTL1 4874/4885MAPT 1753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.